The reasons to adopt an FSP model have never been more apparent than they are today. The benefits have been proven: enhanced productivity, operational ease-of-use, reduction of risk, simplified financial management, accelerated timelines and more. In addition to these measurable metrics, the FSP model creates a culture of trust, emphasizing open communication, transparency, proactive responsibility, and leadership. It also enables collaboration beyond a traditional outsourcing model, as skilled, embedded staff are heavily invested in successful outcomes.
For more than a decade, Synteract has been providing functional support services to clients across the United States and Europe. Our FSP model offers experienced, dedicated staff with leading industry expertise to deliver clinical studies according to a plan. Join Theo Erasmus, Vice President of Biometrics FSP, and Alex Brink, Executive Director of Biometrics, for our upcoming webinar, Achieving Scalability and Reducing Costs with an FSP Model, on June 23, 2020.
Discover why organizations from small bio-techs to global pharmas have used the FSP model to achieve creative, customized solutions that drive their success.
Theo Erasmus, Vice President, Biostatistics FSP, Synteract
As the vice president of biometrics FSP, Theo Erasmus is responsible for the Biometrics FSP go-to-market strategy and the client face for the Synteract Biometrics FSP solution. Erasmus has over 25 years of CRO experience including Biometrics and FSP experience with large and mid-size pharma and has successfully built and delivered the Biometrics FSP solutions in his previous roles at a large CRO.
Erasmus’s previous roles and experience include providing strategic leadership for Clinvet and various other companies in the Clin Group. Prior to that, Erasmus led data management and biostatistical teams for a large CRO, managing key customer accounts and meeting customer requirements and expectations. Erasmus was responsible for financial, operations, employee quality goals and objectives, and growing the business, as well as serving on global leadership teams and boards of directors.
Erasmus holds Bachelor of Science (Honors) in Mathematical Statistics and Master of Medical Science in Pharmacology, both from the University of the Free State in South Africa.Message Presenter
Alex Brink, Executive Director, Biometrics, South Africa & Sri Lanka, Synteract
Alex Brink brings nearly 15 years of Biometrics delivery experience to his role as the executive director of biometrics in South Africa and Sri Lanka at Synteract. Previously, Brink was the head of Biometrics CRO Clindata, and was accountable and responsible for providing strategic guidance for all aspects of the business and service delivery. Prior to that, Brink held varying positions of increasing responsibility in the Biostatistics team at a large CRO, notably as the analysis & reporting customer relationship manager for one of the CRO’s biggest biostatistics customers. Brink’s operational experience as study statistician and study programmer includes PK/PD analyses, PK parameter estimation and randomization across all phases and multiple therapeutic areas, most notably Oncology.
Alex holds a Master of Commerce (MCom) degree in Statistics from the University of the Free State in South Africa.Message Presenter
Who Should Attend?
This webinar will appeal to VPs, Directors, Managers, Department Heads, Scientists and Researchers working within:
- Clinical Affairs
- Clinical R&D
- Clinical Research
- Clinical Pharmacology
- Clinical Operations
- Project Management
- Regulatory Affairs
- Medical Affairs
What You Will Learn
This free webinar will:
- Provide an in-depth look at the four pillars of FSP success
- Examine ways the FSP model encourages flexible thinking and problem solving
- Explore how the FSP model creates more predictable outcomes
- Discover ways the FSP model uniquely lends itself to high-quality resourcing and recruitment
With employees across 21 countries, Synteract is an innovative, full-service CRO supporting biopharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and 750,000 patients. Greater than 245 of its 4,000 studies have been in pediatric populations. In addition to pediatrics clinical trials, Synteract offers a notable depth of therapeutic expertise in dermatology, neurodegenerative, oncology and immunotherapy, and rare/orphan disease studies.